SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-23-045748
Filing Date
2023-06-02
Accepted
2023-06-02 16:05:30
Documents
12
Period of Report
2023-05-26
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea179697-8k_nektar.htm   iXBRL 8-K 26398
  Complete submission text file 0001213900-23-045748.txt   198138

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE nktr-20230526.xsd EX-101.SCH 2953
3 XBRL LABEL FILE nktr-20230526_lab.xml EX-101.LAB 34240
4 XBRL PRESENTATION FILE nktr-20230526_pre.xml EX-101.PRE 22355
6 EXTRACTED XBRL INSTANCE DOCUMENT ea179697-8k_nektar_htm.xml XML 3489
Mailing Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158
Business Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158 4154825300
NEKTAR THERAPEUTICS (Filer) CIK: 0000906709 (see all company filings)

IRS No.: 943134940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-24006 | Film No.: 23988651
SIC: 2834 Pharmaceutical Preparations